nilvadipine has been researched along with Left Ventricular Hypertrophy in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compared the effects of 1 year of monotherapy with a calcium-channel antagonist (nilvadipine; NIL), an angiotensin-converting enzyme (ACE) inhibitor (temocapril; TEM), or a new vasodilator (cadralazine; CAD) on left ventricular (LV) hypertrophy in essential hypertension." | 5.08 | The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. ( Inoue, H; Oh-hashi, S; Takata, M; Tomita, S; Ueno, H; Yasumoto, K, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ueno, H | 1 |
| Takata, M | 1 |
| Tomita, S | 1 |
| Oh-hashi, S | 1 |
| Yasumoto, K | 1 |
| Inoue, H | 1 |
1 trial available for nilvadipine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial | 1997 |